Deprescribing Advanced Therapies in Inflammatory Bowel Diseas

Key Takeaways: • Deprescribing advanced therapies is a viable option for carefully-selected patients living with IBD. • We propose a systematic approach for deprescribing advanced therapies in IBD, which comprises strategic patient selection, comprehensive risk assessment, shared decision-making, rigorous monitoring, and a pre-defined rescue strategy. • Further research is needed to improve patient selection tools, optimize monitoring techniques, and clarify deprescribing strategies for newer agents.